線維芽細胞活性化タンパク質阻害剤の世界市場レポート 2025年

線維芽細胞活性化タンパク質阻害剤市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は9.7%で、43億7,000万米ドルに成長します。予測期間の成長は、線維芽細胞活性化タンパク質（FAP）阻害剤のパイプラインの拡大、がん以外の疾患への幅広い応用、併用療法の増加、がん研究に対する政府資金の増加、製薬企業の関心の高まりに起因します。この期間に予想される主な動向には、標的ドラッグデリバリーシステムの発展、次世代FAP阻害剤の開発、コンパニオン診断技術の革新、免疫療法併用戦略の進展、患者のコンプライアンスを高める経口デリバリーオプションの処方などがあります。

がんの罹患率の上昇は、今後数年間における線維芽細胞活性化タンパク質（FAP）阻害剤市場の成長を促進すると予想されます。がんは、周囲の組織に侵入し、身体の他の部分に広がる可能性のある異常細胞の制御不能な増殖を特徴とし、様々な組織に発生し、その細胞または発生組織に基づいて分類されます。がん患者数の増加は、人口の高齢化、ライフスタイルの変化、環境暴露、診断方法の改善などの要因によるものです。FAP阻害剤は腫瘍を支持する線維芽細胞を標的とするため腫瘍学で使用され、それによって画像診断とがん治療薬の送達の両方が強化されます。例えば、2024年8月、英国を拠点とする慈善団体マクミラン・キャンサー・サポートは、2024年には英国で300万人以上ががんと共に生活していると報告し、この数は2025年には350万人、2030年には400万人、2040年には530万人に増加すると予測しています。その結果、がん罹患率の増加がFAP阻害剤市場の拡大に拍車をかけています。

線維芽細胞活性化タンパク質（FAP）阻害剤市場の主要企業は、放射性医薬品の送達精度を高め、画像診断の精度を向上させ、がん治療における治療効果を高めるために、FAPを標的とするSARキレーター技術を取り入れるようになってきています。SARキレーター技術は、放射性金属を確実に結合させる特殊な分子を使用するもので、研究者は構造変化が薬物の性能にどのように影響するかを評価することができます。この技術は主に、イメージングや治療目的で放射性薬剤をがん細胞に直接誘導するために応用されています。例えば、2024年12月、オーストラリアを拠点とする放射性医薬品会社クラリティ・ファーマシューティカルズは、革新的なFAP標的放射性医薬品を発表しました。この新規薬剤は、クラリティ社の臨床パイプラインを拡大し、FAPの発現が亢進しているがんに対する高度に選択的な治療選択肢を提供するもので、診断の明瞭性と治療効果の両方を高める可能性があります。このマイルストーンは、個別化がん治療をサポートする放射性医薬品の開発に対するクラリティの継続的なコミットメントを反映しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の線維芽細胞活性化タンパク質阻害剤：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の線維芽細胞活性化タンパク質阻害剤市場：成長率分析
• 世界の線維芽細胞活性化タンパク質阻害剤市場の実績：規模と成長、2019年～2024年
• 世界の線維芽細胞活性化タンパク質阻害剤市場の予測：規模と成長、2024年～2029年、2034年
• 世界の線維芽細胞活性化タンパク質阻害剤：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の線維芽細胞活性化タンパク質阻害剤市場：タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 低分子阻害剤
• モノクローナル抗体
• ペプチド阻害剤
• 世界の線維芽細胞活性化タンパク質阻害剤市場：適応症別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 間質性膀胱炎
• クローン病
• 過敏性腸症候群
• 慢性前立腺炎
• その他の適応症
• 世界の線維芽細胞活性化タンパク質阻害剤市場：投与経路別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 経口
• 静脈内
• 皮下
• 世界の線維芽細胞活性化タンパク質阻害剤市場：流通チャネル別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界の線維芽細胞活性化タンパク質阻害剤市場：エンドユーザー別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院
• ホームケア
• 専門クリニック
• その他のエンドユーザー
• 世界の線維芽細胞活性化タンパク質阻害剤市場、低分子阻害剤の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• キナーゼ阻害剤
• プロテアーゼ阻害剤
• マルチターゲットエージェント
• 世界の線維芽細胞活性化タンパク質阻害剤市場、モノクローナル抗体の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• ヒト化抗体
• 完全ヒト抗体
• 二重特異性抗体
• 世界の線維芽細胞活性化タンパク質阻害剤市場、ペプチド阻害剤の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• 合成ペプチド
• 天然ペプチド誘導体
• ペプチドベースのコンジュゲート

第7章 地域別・国別分析

• 世界の線維芽細胞活性化タンパク質阻害剤市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 世界の線維芽細胞活性化タンパク質阻害剤市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 線維芽細胞活性化タンパク質阻害剤市場：競合情勢
• 線維芽細胞活性化タンパク質阻害剤市場：企業プロファイル
  • Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Jazz Pharmaceuticals Inc.
• Prestige Consumer Healthcare Inc.
• SOFIE Biosciences Inc.
• Molecular Partners
• FibroGen Inc.
• Elicio Therapeutics Inc.
• Huya Bioscience International
• Agios Pharmaceuticals Inc.
• MedChemExpress
• Boster Biological Technology
• Nordic Nanovector
• Ferronova
• InvivoChem
• PsiOxus Therapeutics
• Angion Biomedica Corp.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 線維芽細胞活性化タンパク質阻害剤市場2029年：新たな機会を提供する国
• 線維芽細胞活性化タンパク質阻害剤市場2029年：新たな機会を提供するセグメント
• 線維芽細胞活性化タンパク質阻害剤市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Fibroblast activation protein (FAP) inhibitors are targeted therapies used to treat fibrosis-related conditions by blocking the activity of FAP, a protein involved in tissue scarring. As small-molecule inhibitors, they work by specifically inhibiting FAP to reduce the formation of excess fibrous tissue, thereby helping to preserve or improve organ function by slowing the progression of fibrosis.

The primary types of fibroblast activation protein inhibitors include small molecule inhibitors, monoclonal antibodies, and peptide inhibitors. Small molecule inhibitors are low molecular weight compounds that can effectively penetrate cells to inhibit FAP's enzymatic activity. These inhibitors are being investigated for various conditions such as interstitial cystitis, Crohn's disease, irritable bowel syndrome, chronic prostatitis, and others. They can be administered through different routes, including oral, intravenous, and subcutaneous methods. Distribution channels include hospital pharmacies, online pharmacies, and retail pharmacies, with use spanning multiple healthcare settings such as hospitals, homecare, specialty clinics, and more.

The fibroblast activation protein inhibitors market research report is one of a series of new reports from The Business Research Company that provides fibroblast activation protein inhibitors market statistics, including the fibroblast activation protein inhibitors industry global market size, regional shares, competitors with the fibroblast activation protein inhibitors market share, detailed fibroblast activation protein inhibitors market segments, market trends, and opportunities, and any further data you may need to thrive in the fibroblast activation protein inhibitors industry. This fibroblast activation protein inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The fibroblast activation protein inhibitors market size has grown rapidly in recent years. It will grow from $2.74 billion in 2024 to $3.02 billion in 2025 at a compound annual growth rate (CAGR) of 10.0%. Growth during the historic period can be attributed to the growing emphasis on personalized medicine, increased investment in oncology drug discovery, the advancement of biomarker-based drug development, expanding collaboration among biotechnology companies, and heightened interest in targeting the tumor stroma as a therapeutic approach.

The fibroblast activation protein inhibitors market size is expected to see strong growth in the next few years. It will grow to $4.37 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. Growth in the forecast period can be attributed to the expanding pipeline of fibroblast activation protein (FAP) inhibitors, broader applications in non-oncology conditions, increasing use of combination therapies, rising government funding for cancer research, and growing interest from pharmaceutical companies. Key trends expected during this period include advancements in targeted drug delivery systems, the development of next-generation FAP inhibitors, innovation in companion diagnostic technologies, progress in immunotherapy combination strategies, and the formulation of oral delivery options to enhance patient compliance.

The rising incidence of cancer is expected to drive the growth of the fibroblast activation protein (FAP) inhibitors market in the coming years. Cancer is characterized by the uncontrolled growth of abnormal cells that can invade surrounding tissues and spread to other parts of the body, originating in various tissues and classified based on their cell or tissue of origin. The growing number of cancer cases is attributed to factors such as aging populations, lifestyle changes, environmental exposures, and improvements in diagnostic methods. FAP inhibitors are used in oncology to target tumor-supporting fibroblasts, thereby enhancing both diagnostic imaging and the delivery of cancer therapies. For example, in August 2024, Macmillan Cancer Support, a UK-based charitable organization, reported that over 3 million people in the UK were living with cancer in 2024, with projections indicating this number will rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the increasing incidence of cancer is fueling the expansion of the FAP inhibitors market.

Leading companies in the fibroblast activation protein (FAP) inhibitors market are increasingly incorporating SAR chelator technology with FAP targeting to enhance the precision of radiopharmaceutical delivery, improve diagnostic imaging accuracy, and boost therapeutic effectiveness in cancer treatment. SAR chelator technology involves the use of specialized molecules that securely bind radioactive metals, enabling researchers to assess how structural changes influence drug performance. This technology is primarily applied to guide radioactive agents directly to cancer cells for imaging or therapeutic purposes. For example, in December 2024, Clarity Pharmaceuticals, an Australia-based radiopharmaceutical company, introduced its innovative FAP-targeted radiopharmaceutical-an advanced therapy developed for precision oncology. This novel agent broadens Clarity's clinical pipeline and provides a highly selective treatment option for cancers exhibiting elevated FAP expression, with the potential to enhance both diagnostic clarity and treatment efficacy. This milestone reflects Clarity's ongoing commitment to developing radiopharmaceuticals that support personalized cancer care.

In March 2025, Telix Pharmaceuticals Ltd., an Australia-based radiopharmaceutical company, acquired a portfolio of fibroblast activation protein (FAP)-targeting theranostic radiopharmaceutical candidates developed by Professor Frank Rosch and his team at Johannes Gutenberg University Mainz. The financial terms of the deal were not disclosed. This acquisition is intended to leverage Telix's global commercial capabilities and expertise in theranostics to accelerate the development of FAP-targeting agents. The acquired portfolio includes both preclinical and clinical-stage candidates designed for the imaging and treatment of various cancers. Johannes Gutenberg University Mainz, based in Germany, is recognized for its specialization in nuclear chemistry.

Major players in the fibroblast activation protein inhibitors market are Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Jazz Pharmaceuticals Inc., Prestige Consumer Healthcare Inc., SOFIE Biosciences Inc., Molecular Partners, FibroGen Inc., Elicio Therapeutics Inc., Huya Bioscience International, Agios Pharmaceuticals Inc., MedChemExpress, Boster Biological Technology, Nordic Nanovector, Ferronova, InvivoChem, PsiOxus Therapeutics, and Angion Biomedica Corp.

North America was the largest region in the fibroblast activation protein inhibitors market in 2024. The regions covered in fibroblast activation protein inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the fibroblast activation protein inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The fibroblast activation protein inhibitors market consists of sales of antibody-drug conjugates, radiolabeled inhibitors, and combination therapies targeting fibroblast activation protein. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Fibroblast Activation Protein Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on fibroblast activation protein inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for fibroblast activation protein inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The fibroblast activation protein inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Small Molecule Inhibitors; Monoclonal Antibodies; Peptide Inhibitors
• 2) By Indication: Interstitial Cystitis; Crohn's; Irritable Bowel; Chronic Prostatitis; Other Indications
• 3) By Route Of Administration: Oral; Intravenous; Subcutaneous
• 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Small Molecule Inhibitors: Kinase Inhibitors; Protease Inhibitors; Multi-Targeted Agents
• 2) By Monoclonal Antibodies: Humanized Antibodies; Fully Human Antibodies; Bispecific Antibodies
• 3) By Peptide Inhibitors: Synthetic Peptides; Natural Peptide Derivatives; Peptide-Based Conjugates
• Companies Mentioned: Roche Ltd.; Bristol-Myers Squibb Company; AstraZeneca plc; Novartis AG; Teva Pharmaceutical Industries Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Fibroblast Activation Protein Inhibitors Market Characteristics

3. Fibroblast Activation Protein Inhibitors Market Trends And Strategies

4. Fibroblast Activation Protein Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Fibroblast Activation Protein Inhibitors Growth Analysis And Strategic Analysis Framework

• 5.1. Global Fibroblast Activation Protein Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Fibroblast Activation Protein Inhibitors Market Growth Rate Analysis
• 5.4. Global Fibroblast Activation Protein Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Fibroblast Activation Protein Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Fibroblast Activation Protein Inhibitors Total Addressable Market (TAM)

6. Fibroblast Activation Protein Inhibitors Market Segmentation

• 6.1. Global Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Small Molecule Inhibitors
• Monoclonal Antibodies
• Peptide Inhibitors
• 6.2. Global Fibroblast Activation Protein Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Interstitial Cystitis
• Crohn's
• Irritable Bowel
• Chronic Prostatitis
• Other Indications
• 6.3. Global Fibroblast Activation Protein Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Subcutaneous
• 6.4. Global Fibroblast Activation Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• 6.5. Global Fibroblast Activation Protein Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users
• 6.6. Global Fibroblast Activation Protein Inhibitors Market, Sub-Segmentation Of Small Molecule Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Kinase Inhibitors
• Protease Inhibitors
• Multi-Targeted Agents
• 6.7. Global Fibroblast Activation Protein Inhibitors Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Humanized Antibodies
• Fully Human Antibodies
• Bispecific Antibodies
• 6.8. Global Fibroblast Activation Protein Inhibitors Market, Sub-Segmentation Of Peptide Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Synthetic Peptides
• Natural Peptide Derivatives
• Peptide-Based Conjugates

7. Fibroblast Activation Protein Inhibitors Market Regional And Country Analysis

• 7.1. Global Fibroblast Activation Protein Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Fibroblast Activation Protein Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Fibroblast Activation Protein Inhibitors Market

• 8.1. Asia-Pacific Fibroblast Activation Protein Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Fibroblast Activation Protein Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Fibroblast Activation Protein Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Fibroblast Activation Protein Inhibitors Market

• 9.1. China Fibroblast Activation Protein Inhibitors Market Overview
• 9.2. China Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Fibroblast Activation Protein Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Fibroblast Activation Protein Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Fibroblast Activation Protein Inhibitors Market

• 10.1. India Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Fibroblast Activation Protein Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Fibroblast Activation Protein Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Fibroblast Activation Protein Inhibitors Market

• 11.1. Japan Fibroblast Activation Protein Inhibitors Market Overview
• 11.2. Japan Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Fibroblast Activation Protein Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Fibroblast Activation Protein Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Fibroblast Activation Protein Inhibitors Market

• 12.1. Australia Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Fibroblast Activation Protein Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Fibroblast Activation Protein Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Fibroblast Activation Protein Inhibitors Market

• 13.1. Indonesia Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Fibroblast Activation Protein Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Fibroblast Activation Protein Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Fibroblast Activation Protein Inhibitors Market

• 14.1. South Korea Fibroblast Activation Protein Inhibitors Market Overview
• 14.2. South Korea Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Fibroblast Activation Protein Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Fibroblast Activation Protein Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Fibroblast Activation Protein Inhibitors Market

• 15.1. Western Europe Fibroblast Activation Protein Inhibitors Market Overview
• 15.2. Western Europe Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Fibroblast Activation Protein Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Fibroblast Activation Protein Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Fibroblast Activation Protein Inhibitors Market

• 16.1. UK Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Fibroblast Activation Protein Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Fibroblast Activation Protein Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Fibroblast Activation Protein Inhibitors Market

• 17.1. Germany Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Fibroblast Activation Protein Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Fibroblast Activation Protein Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Fibroblast Activation Protein Inhibitors Market

• 18.1. France Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Fibroblast Activation Protein Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Fibroblast Activation Protein Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Fibroblast Activation Protein Inhibitors Market

• 19.1. Italy Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Fibroblast Activation Protein Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Fibroblast Activation Protein Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Fibroblast Activation Protein Inhibitors Market

• 20.1. Spain Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Fibroblast Activation Protein Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Fibroblast Activation Protein Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Fibroblast Activation Protein Inhibitors Market

• 21.1. Eastern Europe Fibroblast Activation Protein Inhibitors Market Overview
• 21.2. Eastern Europe Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Fibroblast Activation Protein Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Fibroblast Activation Protein Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Fibroblast Activation Protein Inhibitors Market

• 22.1. Russia Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Fibroblast Activation Protein Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Fibroblast Activation Protein Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Fibroblast Activation Protein Inhibitors Market

• 23.1. North America Fibroblast Activation Protein Inhibitors Market Overview
• 23.2. North America Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Fibroblast Activation Protein Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Fibroblast Activation Protein Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Fibroblast Activation Protein Inhibitors Market

• 24.1. USA Fibroblast Activation Protein Inhibitors Market Overview
• 24.2. USA Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Fibroblast Activation Protein Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Fibroblast Activation Protein Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Fibroblast Activation Protein Inhibitors Market

• 25.1. Canada Fibroblast Activation Protein Inhibitors Market Overview
• 25.2. Canada Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Fibroblast Activation Protein Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Fibroblast Activation Protein Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Fibroblast Activation Protein Inhibitors Market

• 26.1. South America Fibroblast Activation Protein Inhibitors Market Overview
• 26.2. South America Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Fibroblast Activation Protein Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Fibroblast Activation Protein Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Fibroblast Activation Protein Inhibitors Market

• 27.1. Brazil Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Fibroblast Activation Protein Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Fibroblast Activation Protein Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Fibroblast Activation Protein Inhibitors Market

• 28.1. Middle East Fibroblast Activation Protein Inhibitors Market Overview
• 28.2. Middle East Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Fibroblast Activation Protein Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Fibroblast Activation Protein Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Fibroblast Activation Protein Inhibitors Market

• 29.1. Africa Fibroblast Activation Protein Inhibitors Market Overview
• 29.2. Africa Fibroblast Activation Protein Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Fibroblast Activation Protein Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Fibroblast Activation Protein Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Fibroblast Activation Protein Inhibitors Market Competitive Landscape And Company Profiles

• 30.1. Fibroblast Activation Protein Inhibitors Market Competitive Landscape
• 30.2. Fibroblast Activation Protein Inhibitors Market Company Profiles
  • 30.2.1. Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Fibroblast Activation Protein Inhibitors Market Other Major And Innovative Companies

• 31.1. Jazz Pharmaceuticals Inc.
• 31.2. Prestige Consumer Healthcare Inc.
• 31.3. SOFIE Biosciences Inc.
• 31.4. Molecular Partners
• 31.5. FibroGen Inc.
• 31.6. Elicio Therapeutics Inc.
• 31.7. Huya Bioscience International
• 31.8. Agios Pharmaceuticals Inc.
• 31.9. MedChemExpress
• 31.10. Boster Biological Technology
• 31.11. Nordic Nanovector
• 31.12. Ferronova
• 31.13. InvivoChem
• 31.14. PsiOxus Therapeutics
• 31.15. Angion Biomedica Corp.

32. Global Fibroblast Activation Protein Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Fibroblast Activation Protein Inhibitors Market

34. Recent Developments In The Fibroblast Activation Protein Inhibitors Market

35. Fibroblast Activation Protein Inhibitors Market High Potential Countries, Segments and Strategies

• 35.1 Fibroblast Activation Protein Inhibitors Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Fibroblast Activation Protein Inhibitors Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Fibroblast Activation Protein Inhibitors Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer